Maureen A. Dillon

发表

Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?

P. Raggi, G. Chertow, S. Chasan-Taber, 2002, Journal of the American College of Cardiology.

A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.

B. Garrett, E. Slatopolsky, A. Bleyer, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.

W. Suki, S. Chasan-Taber, S. Burke, 2007, Kidney international.

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.

J. Isaacsohn, B. Gordon, S. Weiss, 1999, Archives of internal medicine.

A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis

S. Goyal, M. Moustafa, Mark T. Smith, 2014, International journal of nephrology and renovascular disease.

Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.

Margit S Rezabek, Doug Hemken, S. Burke, 2003, Advances in renal replacement therapy.

Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial.

G. Chertow, S. Burke, N. Amin, 2000, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

N. Chen, Xuemei Li, Xiaoqiang Ding, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.

E. Slatopolsky, S. Burke, M. Dillon, 1999, Kidney international.

Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.

M. Weinberg, B. Garrett, E. Slatopolsky, 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.

M. Plone, S. Burke, A. Blair, 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients.

G. Chertow, E. Slatopolsky, S. Burke, 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients.

B. Garrett, G. Chertow, E. Slatopolsky, 1999, Clinical nephrology.

Hyperparathyroidism and dialysis vintage.

G. Chertow, E. Slatopolsky, M. Plone, 2000, Clinical nephrology.

End-Stage Renal Disease Cardiac Calcification in Adult Hemodialysis Patients

G. Chertow, S. Chasan-Taber, S. Burke, 2016 .